targeted pharmacological depletion serum amyloid p component treatment human amyloidosis 
normal plasma protein serum amyloid p component sap binds fibrils types amyloid deposits contributes pathogenesis amyloidosis order intervene process developed drug r--[-[r--carboxy-pyrrolidin--yl]--oxo-hexanoyl] pyrrolidine--carboxylic acid competitive inhibitor sap binding amyloid fibrils palindromic compound also crosslinks dimerizes sap molecules leading rapid clearance liver thus produces marked depletion circulating human sap mechanism drug action potently removes sap human amyloid deposits tissues may provide new therapeutic approach systemic amyloidosis diseases associated local amyloid including alzheimers disease type diabetes 
